US Patent

US10717721 — Substituted piperaziniums for the treatment of emesis

Composition of Matter · Assigned to Helsinn Healthcare SA · Expires 2032-05-23 · 6y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds with the general formula (I) that prevent and/or treat diseases mediated by the neurokinin (NK 1) receptor.

USPTO Abstract

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK 1 ) receptor. The compounds have the general formula (I):

Drugs covered by this patent

fosnetupitant-chloride-hydrochloride (FOSNETUPITANT CHLORIDE HYDROCHLORIDE)

Patent Metadata

Patent number: US10717721
Jurisdiction: US
Classification: Composition of Matter
Expires: 2032-05-23
Drug substance claim: Yes
Drug product claim: No
Assignee: Helsinn Healthcare SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.